Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...

Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...

Management continues to anticipate the presentation of three-year OpRegen trial data in June 2025, with Culley expressing hope it will “provide additional conviction in our approach.” There remains no ...

Rapid developments in gene-modified cell therapies, especially CAR T-cell therapies, has increased demand for fast and reliable analytics methods for research, in-process development, and ...